Geoffrey Gilmartin

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial

Eugene R. Bleecker, J. Mark FitzGerald, Pascal Chanez et al. · The Lancet · 2016 · 1.4K citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial

J. Mark FitzGerald, Eugene R. Bleecker, Parameswaran Nair et al. · The Lancet · 2016 · 1.4K citations

Pharmacy, Immunology, Pharmacology +17

Efficacy and safety of ivacaftor in patients with cystic fibrosis and a non-G551D gating mutation

K. De Boeck, À. Munck, Seth Walker et al. · Journal of Cystic Fibrosis · 2014 · 386 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Long-term safety and efficacy of ivacaftor in patients with cystic fibrosis who have the Gly551Asp-CFTR mutation: a phase 3, open-label extension study (PERSIST)

Edward F. McKone, Drucy Borowitz, Pavel Dřevı́nek et al. · The Lancet Respiratory Medicine · 2014 · 211 citations

Medicine, Pharmacology, Pharmacotherapy +16

Differentiating Obstructive from Central and Complex Sleep Apnea Using an Automated Electrocardiogram-Based Method

Robert J. Thomas, Joseph E. Mietus, Chung‐Kang Peng et al. · SLEEP · 2007 · 183 citations · Full text

Medicine, Physiology, Biomedical Signal Processing +16